Chicago partner David Sudzus and Chicago associate Russ Chibe authored an article for RX for the Defense titled “Spotlight on the Opioid Litigation: A National Opioid Emergency: What Lies Ahead for the Pharmaceutical Industry?” In the article, they discuss the recent move by the Trump administration to declare a national emergency in response to widespread opioid abuse in the United States.

As Dave and Russ explain, efforts to combat opioid abuse could target the pharmaceutical industry, the doctors who prescribe the drugs, or the users themselves, and there are many ways the pharmaceutical industry could be affected. It isn’t yet clear how the Trump administration will proceed, but in the meantime, Dave and Russ encourage pharmaceutical companies and their outside counsel to keep a close eye on new developments.

Read the article.

Source: RX for the Defense
Leave Drinker Biddle to Learn More